Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker PBYI
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 6, 2026 | SCHEDULE 13D/A (amended) | PBYI Puma Biotechnology Inc | Alan H. Auerbach | 8.65M | 16.0% | SCHEDULE 13D/A ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Apr 17, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | BlackRock, Inc. | 2.78M | 5.6% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Stephen DuBois | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Camber Capital Management LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Acorn Capital Advisors GP 2, LLC | 285,229 | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Anders Hove | 3.94M | 8.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Acorn Capital Advisors GP, LLC | 1.65M | 3.3% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Acorn Bioventures 2, L.P. | 2.29M | 4.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Acorn Bioventures, L.P. | 1.65M | 3.3% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Daniel Estes | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | James Brush | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Albert Cha | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Patrick J. Heron | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | James N. Topper | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Fhmls Xi, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Fhmls Xi, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Frazier Life Sciences XI, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Fhmls X, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Fhmls X, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Frazier Life Sciences X, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Fhmlsp, L.L.C. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Fhmlsp, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Frazier Life Sciences Public Fund, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 3, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Israel A. Englander | 1.89M | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 3, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Millennium Group Management LLC | 1.89M | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 3, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Millennium Management LLC | 1.89M | 3.9% | SCHEDULE 13G/A ↗ |
| Feb 3, 2025 | SCHEDULE 13G/A (amended) | PBYI Puma Biotechnology Inc | Integrated Core Strategies (US) LLC | 1.39M | 2.8% | SCHEDULE 13G/A ↗ |
28 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 4:01 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances